EUCTR2011-005698-21-HR进行中（未招募）1 期
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Effect of Alirocumab (SAR236553/REGN727) on the Occurrence of Cardiovascular Events in Patients Who Have Recently Experienced an Acute Coronary Syndrome
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 18,924
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
入选标准
- •o Recently (< 52 weeks) hospitalized for ACS.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 16000
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 2600
排除标准
- •o Age < 40 years.
- •o ACS event occurring more than 52 weeks prior to randomization visit.
- •o LDL-C likely to be <70 mg/dL (<1.81 mmo/L) with evidence-based medical and dietary management of dyslipidemia.
研究者
相似试验
进行中（未招募）
不适用
Efficacy and Safety of SAR236553 (REGN727) Versus Placebo on Top of Lipid-Modifying Therapy in Patients with Heterozygous Familial HypercholesterolemiaHypercholesterolaemiaMedDRA version: 15.1Level: PTClassification code 10020603Term: HypercholesterolaemiaSystem Organ Class: 10027433 - Metabolism and nutrition disordersEUCTR2011-005109-56-GBsanofi-aventis Recherche & Développement802
进行中（未招募）
1 期
A study of Baricitinib in patients with LupusSystemic Lupus Erythematosus (SLE)MedDRA version: 21.1Level: LLTClassification code 10025139Term: Lupus erythematosus systemicSystem Organ Class: 100000004859EUCTR2017-005026-37-GREli Lilly and Company821
进行中（未招募）
1 期
albuphine HCL ER Tablets in Prurigo Nodularis PatientsPrurigo NodularisEUCTR2013-005627-17-DETrevi Therapeutics, Inc.60
进行中（未招募）
1 期
A study in LupusPatients with Systemic Lupus Erythematosus (SLE)MedDRA version: 18.1Level: LLTClassification code 10025139Term: Lupus erythematosus systemicSystem Organ Class: 100000004859EUCTR2015-004404-35-ESilly S.A.300
进行中（未招募）
不适用
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging, Multicenter Study of the Efficacy of RWJ-333369 in the Prophylaxis of Migraine - Efficacy study of 333369 for the Prophylaxis of MigraineEUCTR2004-004162-33-DEJanssen Cilag International NV300